# High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

> **NCT05379803** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT05379803
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05379803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05379803, "High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05379803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*